A new rat model of thrombotic focal cerebral ischemia.
We developed a fibrin-rich thrombotic focal cerebral ischemic model with reproducible and predictable infarct volume in rats. In male Wistar rats (n = 77), a thrombus was induced at the origin of the middle cerebral artery (MCA) by injection of thrombin via an intraluminal catheter placed in the intracranial segment of the internal carotid artery (ICA). Thrombus induction and consequent ischemic cell damage were examined by histopathological analysis and neurological deficit scoring, and by measuring changes in cerebral blood flow (CBF) using laser-Doppler flowmetery (LDF), perfusion-weighted imaging (PWI), and by diffusion weighted imaging (DWI). Histopathology revealed that a fibrin-rich thrombus localized to the origin of the right MCA. Regional cerebral blood flow (rCBF) in the right parietal cortex was reduced by 34-58% of preinjection levels after injection of thrombin in rats administered 30 U of thrombin (n = 10). Magnetic resonance imaging (MRI) showed a reduction in CBF and a hyperintensity DWI encompassing the territory supplied by the right MCA. The infarct volume in rats administered 80 U of thrombin was 31.29 +/- 12.9% of the contralateral hemisphere at 24 h (n = 13), and 34.7 +/- 16.4% of the contralateral hemisphere at 168 h (n = 6). Rats administered 30 U of thrombin exhibited a hemispheric infarct volume of 34.0 +/- 14.5% (n = 9) at 24 h and 29.7 +/- 13.9% (n = 8) at 168 h. In addition, thrombotic rats (n = 3) treated with recombinant tissue plasminogen activator (rt-PA) (10 mg/kg) 2 h after thrombosis showed that CBF rapidly returned towards preischemic values as measured by PWI. This model of thrombotic ischemia is relevant to thromboembolic stroke in humans and may be useful in documenting the safety and efficacy of thrombolytic intervention as well as for investigating therapies complementary to antithrombotic therapy.
Zhang
Z
Z
Department of Neurology, Henry Ford Health Science Center, Detroit, Michigan, USA.
Zhang
R L
RL
Jiang
Q
Q
Raman
S B
SB
Cantwell
L
L
Chopp
M
M
D000818:Animals; D001929:Brain Edema / Q000209:etiology / Q000473:pathology; D002545:Brain Ischemia / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D002343:Carotid Artery, Internal; D002544:Cerebral Infarction / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D004195:Disease Models, Animal; D005337:Fibrin; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D007269:Injections, Intra-Arterial; D002542:Intracranial Embolism and Thrombosis / Q000150:complications* / Q000188:drug therapy / Q000473:pathology; D017078:Laser-Doppler Flowmetry; D008279:Magnetic Resonance Imaging; D008297:Male; D018613:Microscopy, Confocal; D008855:Microscopy, Electron, Scanning; D010296:Parietal Lobe / Q000098:blood supply; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000627:therapeutic use; D015203:Reproducibility of Results; D013917:Thrombin / Q000008:administration & dosage / Q000633:toxicity*; D015912:Thrombolytic Therapy; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D005337:Fibrin; D013917:Thrombin; D010959:Tissue Plasminogen Activator